RNTX

+ Watchlist + Portfolio

Rein Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.85
52-Week Range: $0.69 – $2.18
Market Cap: $69.07M
P/E (TTM): —
EPS (TTM): -1.68
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.73
PEG Ratio: —
Return on Equity: -96.42%
Return on Assets: -21.02%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.27
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-7.79M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $73.43M

RNTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.97M	$3.99M	$14.25M	$11.03M
Selling, General & Admin	$9.68M	$11.36M	$13.86M	$10.90M
Operating Expenses	$27.65M	$15.35M	$28.11M	$21.93M
Operating Income	-$27.65M	-$15.35M	-$28.11M	-$21.93M
EBITDA	-$27.48M	-$15.23M	-$28.05M	-$21.93M
Pretax Income	-$27.33M	-$15.68M	-$64.43M	-$50.58M
Income Tax	—	$0.00	-$1.54M	-$712.00K
Net Income	-$27.33M	-$15.73M	-$62.88M	-$49.87M
Diluted EPS	-6.02	-3.42	-3.51	-1.96
Diluted Shares	4.54M	4.60M	17.94M	25.44M

RNTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.19M	$17.31M	$12.87M	$3.21M
Current Assets	$21.87M	$18.27M	$13.66M	$4.33M
Total Assets	$22.01M	$106.01M	$62.19M	$24.16M
Current Liabilities	$3.38M	$4.38M	$5.75M	$6.18M
Total Debt	$33.00K	$48.00K	$0.00	—
Total Liabilities	$3.38M	$99.12M	$52.80M	$52.24M
Retained Earnings	-$272.79M	-$288.52M	-$351.40M	-$401.27M
Shareholders' Equity	$18.62M	$6.89M	$9.39M	-$28.09M
Working Capital	$18.49M	$13.88M	$7.91M	-$1.85M

RNTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.86M	-$19.81M	-$22.29M	-$19.36M
Free Cash Flow	-$24.86M	-$19.81M	-$22.29M	-$19.36M
Depreciation & Amortisation	$169.00K	$119.00K	$63.00K	$1.00K
Stock-Based Compensation	$2.08M	$1.19M	$1.12M	$2.22M
Investing Cash Flow	$26.46M	$16.20M	$0.00	—
Financing Cash Flow	$0.00	$15.79M	$17.82M	$9.76M
Net Change in Cash	$1.59M	$12.18M	-$4.47M	-$9.61M

RNTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.05M	$4.29M	$1.68M	$2.00M	$3.07M	$3.64M
Selling, General & Admin	$2.56M	$2.58M	$3.81M	$1.96M	$2.16M	$2.44M
Operating Expenses	$5.61M	$6.87M	$5.49M	$3.96M	$5.23M	$6.08M
Operating Income	-$5.61M	-$6.87M	-$5.49M	-$3.96M	-$5.23M	-$6.08M
EBITDA	-$5.61M	-$6.87M	-$5.49M	-$3.96M	-$5.23M	-$6.08M
Pretax Income	-$5.50M	-$6.82M	-$5.58M	-$32.68M	-$5.84M	-$6.38M
Net Income	-$5.50M	-$6.82M	-$5.58M	-$31.97M	-$5.84M	-$6.38M
Diluted EPS	-0.25	-0.28	-0.21	—	-0.19	-0.10
Diluted Shares	21.92M	24.19M	26.36M	—	30.35M	67.08M

RNTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.43M	$5.72M	$4.05M	$3.21M	$4.45M	$8.54M
Current Assets	$8.33M	$6.60M	$5.17M	$4.33M	$5.45M	$41.45M
Total Assets	$57.63M	$57.48M	$53.71M	$24.16M	$26.29M	$65.97M
Current Liabilities	$5.98M	$7.69M	$5.74M	$6.18M	$13.64M	$9.71M
Total Debt	—	—	—	—	$4.92M	—
Total Liabilities	$52.75M	$54.47M	$52.52M	$52.24M	$59.70M	$55.77M
Retained Earnings	-$356.90M	-$363.72M	-$369.30M	-$401.27M	-$407.11M	-$413.48M
Shareholders' Equity	$4.87M	$3.01M	$1.19M	-$28.09M	-$33.41M	$10.20M
Working Capital	$2.35M	-$1.09M	-$570.00K	-$1.85M	-$8.18M	$31.74M
Net Debt	—	—	—	—	$478.00K	—

RNTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$6.17M	-$6.42M	-$3.55M	-$3.22M	-$3.42M	-$8.64M
Free Cash Flow	-$6.17M	-$6.42M	-$3.55M	-$3.22M	-$3.42M	-$8.64M
Depreciation & Amortisation	$0.00	$1.00K	$0.00	$0.00	—	—
Stock-Based Compensation	$264.00K	$256.00K	$1.45M	$257.00K	$156.00K	$164.00K
Financing Cash Flow	$738.00K	$4.71M	$1.90M	$2.40M	$4.65M	$47.81M
Net Change in Cash	-$5.44M	-$1.71M	-$1.65M	-$815.00K	$1.23M	$4.10M

Market Snapshot

About

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for serious diseases. The company utilizes innovative drug discovery platforms and technologies to advance its pipeline of product candidates. Rein Therapeutics aims to address unmet medical needs through its research and development programs.